Language Development Deficits and Early Interactive Music Intervention
Conditions: Dyslexia, Developmental; Language Development Disorders; Language Development Interventions: Behavioral: Music intervention; Behavioral: Circus intervention Sponsors: University of Helsinki; Folkh älsan Research Center; Karolinska Institutet; University of Turku; University of Jyvaskyla; Academy of Finland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
A Study of Biochemical Response to Alternative Proteins
Conditions: Postprandial Hyperglycemia; Overweight and Obesity; Type2diabetes Interventions: Dietary Supplement: High fiber and protein meal; Dietary Supplement: Control Sponsors: University of Eastern Finland Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
HELSINKI, Jan. 26, 2024. Nanoform Finland Plc ( " Nanoform " ), the medicine performance-enhancing company, today announced that one of its leading nanoformulation drug products had received promising clinical results. These were from a relative... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
Effects of Multicomponent Exercise on Subchondral Bone and Cartilage in Postmenopausal Women With Knee Osteoarthritis
Conditions: Osteoarthritis, Knee Interventions: Behavioral: Multicomponent exercise regimen; Behavioral: Standard rehabilitative management Sponsors: University of Jyvaskyla; University of Oulu; Wellbeing Services County of Central Finland; UKK Institute; Research Council of Finland Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
Noninvasive Cortical Neurostimulation For Diabetic Neuropathic Pain
Conditions: Diabetic Neuropathy, Painful; Diabetes Mellitus, Type 1 Interventions: Device: Sooma Oy (tDCS), Helsinki, Finland; Device: Sooma Oy (Sham), Helsinki, Finland Sponsors: Jens Br øndum Frøkjær; Novo Nordisk A/S; Vissing fonden Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
Treatment of Insomnia in Primary Care Study
Conditions: Insomnia Chronic Interventions: Behavioral: Sleep School; Behavioral: Treatment as usual Sponsors: University of Turku; University of Eastern Finland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
ReDirection - Self Help Program for Minor Attracted Individuals
Conditions: Child Abuse Sexual; Pedophilia Interventions: Behavioral: ReDirection Sponsors: Karolinska Institutet; Centre for Psychiatry Research, Region Stockholm, Sweden; Link öping University, Sweden; Universitat Jaume I, Spain; Protect Children Organisation, Finland; National Institute of Mental Health, Czech Republic; Academy of the Police Force, Bratislava, Slovakia; Universitätsklinikum Hamburg-Eppendorf Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
Mi Bridge - Motivational Interviewing to Facilitate Help-seeking Among Minor Attracted Individuals
Conditions: Child Sexual Abuse; Pedophilia Interventions: Behavioral: Behavioral: MiBridge Sponsors: Karolinska Institutet; Centre for Psychiatry Research, Region Stockholm, Sweden; Link öping University, Sweden; Universitat Jaume I, Spain; Protect Children Organisation, Finland; National Institute of Mental Health, Czech Republic; Academy of the Police Force, Bratislava, Slovakia; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
PEPPI Study: Identification of Women at Risk for Placental Dysfunction
Conditions: Pre-Eclampsia; Intrauterine Growth Restriction; Polycystic Ovary Syndrome; Iron-deficiency; Cardiovascular Diseases; Hypertensive Disorder of Pregnancy; Proteinuria in Pregnancy Interventions: Other: Pre-eclampsia screening program Sponsors: Oulu University Hospital; PerkinElmer, Inc.; Roche Diagnostics; Academy of Finland; Sigrid Jus élius Foundation; Finnish Medical Foundation; University of Oulu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Nanoformed TargTex Oncology Drug Candidate TTX101 Receives FDA Orphan Drug Designation
Helsinki, Finland October 19, 2023– Nanoform Finland Plc (Nasdaq Helsinki NANOFH; Nasdaq Stockholm NANOFS), an innovative nanoparticle medicine enabling company, today announced its customer TargTex S.A. has been granted Orphan Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Condition: Multiple Sclerosis (MS) Interventions: Drug: Avonex (IFNβ-1-a, Biogen Netherlands B.V); Drug: Rebif (IFNβ-1-a, Merck Europe B.V.); Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited); Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG); Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V); Drug: MS disease modifying drugs (MSDMDs) Sponsors: Bayer; Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Conditions: Multiple Sclerosis (MS) Interventions: Drug: Avonex (IFN β-1-a, Biogen Netherlands B.V); Drug: Rebif (IFNβ-1-a, Merck Europe B.V.); Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited); Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG); Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V); Drug: MS disease modifying drugs (MSDMDs) Sponsors: Bayer; Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
TURKU, Finland / BOSTON, Massachusetts August 29, 2023 -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the U.S. Food and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 29, 2023 Category: Pharmaceuticals Source Type: clinical trials
